13 results match your criteria: "Toulouse Cancer Research Center[Affiliation]"

Chimeric antigen receptor (CAR) T-cell therapy has transformed the care of patients with relapsed/refractory B-cell-derived hematologic malignancies. To date, six CAR T-cell therapies, targeting either CD19 or B-cell maturation antigen, have received regulatory approval. Along with the promising survival benefit, CAR T-cell therapy is associated with potentially life-threatening adverse events, including cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome.

View Article and Find Full Text PDF

Deleterious association between proton pump inhibitor and protein kinase inhibitor exposure and survival for patients with lung cancer: A nationwide cohort study.

Cancer Treat Res Commun

May 2024

Medical and Clinical Pharmacology Department, Faculty of Medicine, Pharmacovigilance, Pharmacoepidemiology and Drug Information Center, CIC INSERM 1436, Faculty of Medicine, University Hospital Center, 31000, Toulouse, France; University of Toulouse III-Paul Sabatier, 31062, Toulouse, France; Metabolic and Cardiovascular Diseases Institute, French National Health and Medical Research Institute (INSERM), UMR-1048, Toulouse, France. Electronic address:

Introduction: Previous studies have identified an interaction between protein kinase inhibitors (PKIs) and proton pump inhibitors (PPIs) in patients with lung cancer. This type of interaction may reduce the efficacy of PKIs. However, the effect of PKI-PPI interaction on patient mortality remains controversial.

View Article and Find Full Text PDF

Temporal Dynamics and Genomic Landscape of SARS-CoV-2 After Four Years of Evolution.

Cureus

February 2024

Biotechnology Lab (MedBiotech) Bioinova Research Center, Rabat Medical & Pharmacy School, Mohammed V University, Rabat, MAR.

Introduction Since its emergence, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone extensive genomic evolution, impacting public health policies, diagnosis, medication, and vaccine development. This study leverages advanced bioinformatics to assess the virus's temporal and regional genomic evolution from December 2019 to October 2023. Methods Our analysis incorporates 16,575 complete SARS-CoV-2 sequences collected from 214 countries.

View Article and Find Full Text PDF

Lymphocyte migration and retention properties affected by ibrutinib in chronic lymphocytic leukemia.

Haematologica

March 2024

Toulouse Institute for Infectious and Inflammatory Diseases (INFINITy), INSERM, CNRS, Toulouse III Paul Sabatier University, Toulouse, France; Department of Dermatology, Medical University of Vienna, Vienna.

The Bruton tyrosine kinase (BTK) inhibitor ibrutinib is widely used for treatment of patients with relapsed/refractory or treatment-naïve chronic lymphocytic leukemia (CLL). A prominent effect of ibrutinib is to disrupt the retention of CLL cells from supportive lymphoid tissues, by altering BTK-dependent adhesion and migration. To further explore the mechanism of action of ibrutinib and its potential impact on non-leukemic cells, we quantified multiple motility and adhesion parameters of human primary CLL cells and non-leukemic lymphoid cells.

View Article and Find Full Text PDF

Special features of sarcomas developed in patients with Lynch syndrome: A systematic review.

Crit Rev Oncol Hematol

August 2023

Department of Digestive Oncology, University Hospital of Toulouse (IUCT Rangueil Larrey), France; OncoSarc, INSERM U1037, Toulouse Cancer Research Center (CRCT), France. Electronic address:

Article Synopsis
  • Lynch syndrome (LS) is linked to a higher risk of various tumors, including colorectal and non-colorectal cancers, with recent studies suggesting a potential association with sarcomas.
  • A systematic review of 44 studies involving LS patients revealed that most sarcomas developed in individuals with a mutation in the MSH2 gene and showed distinct genetic features typical of LS-related tumors.
  • Among the types of sarcomas observed, undifferentiated pleomorphic sarcoma, leiomyosarcoma, and liposarcoma were the most common, but there was also a notable occurrence of rhabdomyosarcoma, warranting further research to understand this specific group better.
View Article and Find Full Text PDF

Pancreatic Cancer in Chronic Pancreatitis: Pathogenesis and Diagnostic Approach.

Cancers (Basel)

January 2023

Department of Gastroenterology and Pancreatology, CHU Toulouse-Rangueil, University Hospital Centre, Toulouse University, UPS, 31059 Toulouse, France.

Chronic pancreatitis is one of the main risk factors for pancreatic cancer, but it is a rare event. Inflammation and oncogenes work hand in hand as key promoters of this disease. Tobacco is another co-factor.

View Article and Find Full Text PDF

Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor.

Blood

March 2023

Unit for Genomics in Myeloma, University Hospital IUC-Oncopole and Toulouse Cancer Research Center-Oncopole, Toulouse University, INSERM UMR1037, Toulouse, France.

Article Synopsis
  • Cytogenetic abnormalities are key indicators of prognosis in multiple myeloma, with del(1p32) identified as a significant negative factor after del(17p).
  • In a study of 2,551 newly diagnosed patients, those with del(1p32) had a much shorter overall survival (49 months) compared to those without it (124 months).
  • The impact of del(1p32) is even worse for patients with biallelic deletions, leading to a median overall survival of just 25 months, emphasizing the need for thorough assessment at diagnosis for appropriate treatment strategies.
View Article and Find Full Text PDF

Background: There is an unfulfilled need to find the best way to automatically capture, analyze, organize, and merge structural and functional brain magnetic resonance imaging (MRI) data to ultimately extract relevant signals that can assist the medical decision process at the bedside of patients in postanoxic coma. We aimed to develop and validate a deep learning model to leverage multimodal 3D MRI whole-brain times series for an early evaluation of brain damages related to anoxoischemic coma.

Methods: This proof-of-concept, prospective, cohort study was undertaken at the intensive care unit affiliated with the University Hospital (Toulouse, France), between March 2018 and May 2020.

View Article and Find Full Text PDF

Purpose: With current gold standard treatment, which associates maximum safe surgery and chemo-radiation, the large majority of glioblastoma patients relapse within a year in the peritumoral non contrast-enhanced region (NCE). A subpopulation of glioblastoma stem-like cells (GSC) are known to be particularly radio-resistant and aggressive, and are thus suspected to be the cause of these relapses. Previous studies have shown that their distribution is heterogeneous in the NCE compartment, but no study exists on the sensitivity of medical imaging for localizing these cells.

View Article and Find Full Text PDF

Acid sphingomyelinase deficiency (ASMD) is an inherited lysosomal disease characterised by a diffuse accumulation of sphingomyelin that cannot be catabolised into ceramide and phosphocholine. We studied the incidence of cancer in ASMD patients. We retrospectively reviewed the medical records of the adult chronic visceral ASMD patients in our cohort.

View Article and Find Full Text PDF

A diagnosis of progressive myoclonic ataxia guided by blood biomarkers.

Parkinsonism Relat Disord

January 2022

Neuroscience Center, Toulouse University Hospital, Toulouse, France; Toulouse NeuroImaging Center (ToNIC), INSERM-University of Toulouse Paul Sabatier, Toulouse, France. Electronic address:

View Article and Find Full Text PDF

Surgery remains the only curative treatment for pancreatic ductal adenocarcinoma (PDAC). Therefore, a predictive score for resectability on diagnosis is needed. A total of 814 patients were included between 2014 and 2017 from 15 centers included in the BACAP (the national Anatomo-Clinical Database on Pancreatic Adenocarcinoma) prospective cohort.

View Article and Find Full Text PDF

Glioblastomas (GBM) are brain tumors with a poor prognosis despite treatment that combines surgical resection and radio-chemotherapy. These tumors are characterized by abundant vascularization and significant cellular heterogeneity including GBM stem-like cells (GSC) which contribute to tumor aggressiveness, resistance, and recurrence. Recent data has demonstrated that GSC are directly involved in the formation of new vessels via their transdifferentiation into Tumor Derived Endothelial Cells (TDEC).

View Article and Find Full Text PDF